TEE
LRMR icon

Tibra Equities Europe’s Larimar Therapeutics LRMR Stock Holding History

Tibra Equities Europe’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-4,222
Closed -$377K – 161
2018
Q1 		$377K Buy
+4,222
New +$358K 0.07% 154

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Tibra Equities Europe's LRMR Position: Q2 2018 in Review

Tibra Equities Europe sold out of Larimar Therapeutics (LRMR) in Q2 2018, closing a stake of 4,222 shares — an estimated $377K sold.

Tibra Equities Europe first reported a position in LRMR in Q1 2018 and held it in 1 quarter. The position peaked at $377K in Q1 2018. 87 funds tracked by Wall St. Rank hold LRMR as of Q2 2018.

  • Tibra Equities Europe reported no remaining Larimar Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Tibra Equities Europe sold 4,222 Larimar Therapeutics shares in Q2 2018, an estimated $377K.
  • Tibra Equities Europe first reported a position in Larimar Therapeutics in Q1 2018 and held it in 1 quarter.
  • Tibra Equities Europe's Larimar Therapeutics position peaked at $377K in Q1 2018.
  • 87 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2018.

Based on Tibra Equities Europe's 13F filing for Q2 2018, filed 10 Aug 2018.